OTCPK:SPLID - Post by User
Comment by
pointswest2on Dec 30, 2016 11:23pm
163 Views
Post# 25656231
RE:RE:RE:Green to finish the year
RE:RE:RE:Green to finish the year
Note to Jason Things are going to go well for EAT .. dont believe it ..GET OUT ..
The U.K. company GW Pharmaceuticals developed Sativex, the first cannabis derivative to gain market approval in any country, in 2010. The oral spray, which is used to treat spasms and other symptoms of multiple sclerosis, has since been approved in 16 countries and has received regulatory approval in an additional 12 countries — but not in the United States. GW’s latest product, Epidiolex, contains pharmaceutical cannabidiol designed to treat various types of pediatric epilepsy. The FDA recently completed Phase 3 clinical trials that showed promising results. Should Epidiolex get the thumbs-up from the FDA, it would force the DEA to downgrade marijuana from Schedule 1